Next-generation weight loss treatment
New Triple-G Weight Loss Drug Combination Shows Promising Results in Diabetes Patients
Anonymous
Eli Lilly's experimental weight-loss drug retatrutide is showing dramatic results even at low doses. Reuters reported that patients lost an average of 12.7% of their body weight on the lowest dose during trials. The drug works by mimicking hormones that signal fullness after eating, offering a new approach to obesity treatment.
On higher doses, the results get even more impressive. USA Today noted that patients lost nearly 50 pounds on the highest dose of the drug. Eli Lilly said the experimental medication could be submitted to the FDA for approval next year, potentially challenging Novo Nordisk's dominance in the weight-loss drug market.
Triple Hormone Combination Drives Record Weight Loss
Retatrutide works differently than existing weight-loss drugs. WSJ explained that the drug mimics amylin, a hormone that signals fullness after eating. When combined with Zepbound, patients achieved significantly greater weight loss. Zero Hedge reported that the combination delivered up to 23% average weight loss in people with diabetes.
Type 2 Diabetes Patients See Strongest Results
The trial focused on adults with both type 2 diabetes and obesity. Reuters reported they lost an average of nearly 21% of their body weight in the late-stage clinical trial. This marks a major breakthrough for treating obesity in diabetic patients. The combination approach appears to work better than single-hormone drugs currently on the market.
FDA Approval Expected Next Year
Eli Lilly plans to submit retatrutide to the FDA for approval in 2025. NY Post noted the drug is the first of its kind to show these weight-loss levels. The approval would give Lilly a major competitive advantage against Novo Nordisk's popular Ozempic and Wegovy. Industry experts expect the drug to become a blockbuster if approved.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
6
Reach
13
Topics
A
AnonymousAuthor
